Industry News (Patents and Technology)

European Patent Extension Lawsuit Decision Announced

Published in Vaccine Weekly, February 10th, 1997

Biogen, Inc., Massachusetts, announced that the European Court of Justice in Luxembourg has ruled in its favor in a lawsuit on issues related to the extension of Biogen's European hepatitis B antigen patents.

As a result of this decision and national patent legislation that has already passed in select European countries, Biogen expects that its entire European hepatitis B patent portfolio will be extended for an additional one to five years from the original expiration dates, depending on the market.

Jim Vincent, Biogen, said, "We are very pleased by this important decision, which ensures that Biogen will continue to receive all of its current...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-02-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry